1.32
-0.09(-6.38%)
Currency In USD
Address
1 Controls Drive
Shelton, CT 06484
United States of America
Phone
203 937 6137
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
October 26, 2005
| Name | Title | Pay | Year Born |
| Dr. Anil R. Diwan Ph.D. | Executive Chairman, President, Chief Executive Officer & Secretary | 400,000 | 1959 |
| Ms. Meeta R. Vyas B.S., M.B.A., MBA, SB | Chief Financial Officer & Compliance Officer | 129,600 | 1959 |
| Dr. Randall W. Barton Ph.D. | Chief Scientific Officer | 0 | 1947 |
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.